exosome cell program DMD. treatment our Today, first with conference afternoon, Starting provide and and for Good priorities therapy, thank as updates muscular you moving CAP-XXXX, the for outline our I our will call. dystrophy XXXX. our for quarter XXXX well us our of third into joining on as Duchenne platform
that up a stem CAP-XXXX XXX then allogeneic population expanded proprietary of line of is stromal into cells, cells an cardiac is comprised methods using but is not cells, cardiosphere-derived CAP-XXXX tissue doses as from reminder, or derived cells. a of multiple that million are endogenous cell rather CDCs. of made As
few whom therapeutic muscular about perspective, population in group patient or options advanced about is be DMD exploring portfolio is at prioritize as approved XX,XXX Our for patients program. population, of exist. made DMD into CAP-XXXX very Consistent consider men CAP-XXXX for and would younger current program the patient X dystrophy and From neuromuscular we and have management with with up This States. boys Duchenne communications, aimed for diseases. priorities other prior expanding of DMD well key a that believe for patients half with United similar we should the young this our we as our
III trial. First is Phase pivotal the HOPE-X execution our of
the ensure world. as with partnerships to Second United reaches to continuing third to the States is as CAP-XXXX CAP-XXXX with FDA patients bring expeditiously DMD around patients commercial engage is possible. to And outside securing the
clinical function by prior progression in and gold be potentially limb measured standard the in experience function fraction, ejection CAP-XXXX's slow upper shows preserve as presented, heart previously disease ability As cardiac health. is and to which changes to measuring known
our Phase the intravenous infusions. HOPE-X, of we on OLE Project be as the continue of XXX serve for this least be enrolled long-term as as In OLE, Parent with on it is Annual to over of World Phase patients addition, in treat poster study, presented updates podium by double-blind, Muscular in HOPE-X at disease HOPE-X and as profile session treated, safety DMD. extension are which modification the at our Dystrophy backbone States. XX-month powered, otherwise study and X treatment in by trial known safety as to at sites our at II October. our supported presentation at placebo-controlled well This ensure continues pivotal with June to have trial a years the plan data in the possibility further and CAP-XXXX OLE at now a Muscle supported as a well therapy with share trial, at XX CAP-XXXX XX consistent to study. to expect well we was in least open-label III Society to the evidence the the of treatment is our Patients United Further, data in positive Meeting supports with Building randomized, patients. successive approximately To CAP-XXXX these is happy durability to momentum, in potential we investigative for XX results
enrollment and have as investigators study XX drive enrolled are into today. advocacy groups We of actively the patients and with working to
to by We plan the X by enrollments, end to sites bring are the encouraged the pace additional of and, the in active addition on centers, of year.
for on quarter towards to important completion regulatory the FDA is to potential the approval we priority track as continue our with progress and engaging for XXXX. Our guidance equally us enroll Phase our by actively of registration. third remains III on enrollment An program pathway
mentioned, of I of as part recently extension submitted, the XX-month with set As our which, we continuing request, data engagement full FDA, at released. was open-label their have
will updates We on with discussions to FDA. our provide continue
we training see you in that a to inform cost-effective sites versatile completion is launch I We As base this be the subject market enabling last CAP-XXXX future. San tech as a XXXX. to began approval begin of FDA to facility to to and into would CAP-XXXX of for lab as that We manufacturing to expect, first summer larger runs well to the at our and bring able portion GMP this this in transfer way am a CAP-XXXX nearing CAP-XXXX, convert we quarter, early mentioned of qualification quarter pleased up of facility plan will Diego to support construction manufacturing as scale construction I and commercial facility. efficiently.
preparation. conjunction meeting meeting CMC with FDA with in these for a is pre-BLA the efforts, Additionally, request in
commercial Turning partnerships. to our
commercialization this or year U.S. As you entered in may recall, in a DMD earlier Shinyaku, Nippon for the distribution distribution and we into NS Pharma, for rights agreement CAP-XXXX with
trigger to potential These commercialization. starting in payments, should Our strengthen with our if to according move further anticipating prior built balance sheet towards the and in will towards we has Pharma XXXX we completion of achieved, to agreement these NS and milestone approval, as we plan. continue regulatory HOPE-X are milestones several to execute
discussions potential benefit We updates to opportunities believe globally of DMD provide timely are these not our sheet we'll manner. nondilutive partnership if but Europe CAP-XXXX additional potential mature. these committed a a approval markets, maximizing Therefore, are will global in and partnerships, the reaching we and as and to in fashion. We expedite in patients in Asia actively CAP-XXXX balance pursuing path secured, help the for also support will in only
are We very with pleased for CAP-XXXX. progress the
into as path positioned clear well and We deliver X we on XXXX. are move have to our a main forward goals
exosome system like our believe that a turn our communication potentially to therapeutic platform applications. way technology. can drug to delivery cellular nature's transportation, We which exosomes, novel broad with as I'd and serve leverage Now of
expertise to control. progress reproducibility significant the Building we scalability, mediated continue extensive mechanism on our ensuring in and action manufacturing an have learnings We X these and the core the fronts. on and on developed evidence of body production make on which exosomes, program CAP-XXXX, via quality emphasis from exosomes of an and is know-how with for of
foundational targeting. vaccinology very the of payload vaccine without or as first-in-class efforts support and drug for parent's at and proteins therapeutics. immune platform, exosomes quarter, platform foundation vaccines announced the for exosome genetically types modify exosomes intend core technology adjuvant loading the surface it need low elicit of we expression of is of booster exosome-based delivery Earlier exosomes data exosomes potential platform. precision inside StealthX on has broad the the it, delivery of line develop production lipid or this advanced Based other is utilize payloads application the carrier. our true us that we specific COVID-XX. able with this cell for using multivalent our to quarter, to rapidly of This X to proprietary a StealthX the a then allows response dose of trademarked that produces of on platform, with exosome. to this antigen a and nanoparticle innovative therapeutic as for Earlier the downstream modalities: an are support we potent presented we provided a strong for StealthX StealthX, in most methods the that tissue-specific we use further or a have Our unique protein-based a
exosomes, vaccine and on Our cell activity strong nucleocapsid able immune In responses. allowing express studies, that against for their been vaccine antibody to as a spike and proteins surface, both exosomes is preclinical that including have multiple Delta express potentially containing Omicron. we humeral T multivalent as serotypes, neutralizing observe well
multiplexing recently presented. a StealthX-based with of which data, We as plus combined COVID we such demonstrated vaccines, the have platform the also vaccine for power flu
the precision superior The has as the developmental towards vaccines. platform and potential proteins StealthX we We number toxicity or as Our the preclinical lipid nanoparticles, protein both inside a vaccines development this surface relative the are to to the findings to creating potential our synthetic exosome, with speed of of the for human along immune future potential The delivery tools we the are a recapitulated protein us platform, targets. exosome they potential efforts to that will activation coupled mRNA combine platform. believe bioengineered best provide well with support vaccines of our of on to program including mRNA that explore need potential with used of that historical a as synthetic molecules become available. in load the therapeutic the without of this platform vaccine updates will low StealthX has to as to providing differentiated, other both with decorate their to studies, StealthX, allows the forward We ligands next-generation look for those employ therapeutics. compared more exosomes be therapeutic ability If nanoparticles. believe
develop, further As will provide updates. these programs we
as and platform executing these the hopeful alongside business potential our for exosome alliances goals. strategy CAP-XXXX in and intend collaborative opportunities focus StealthX or Approaching end on business development are territories. we as the well We possible XXXX, of partnering, in both therapeutic development, is for objectives and for increasing partnerships vaccine new that efforts Capricor may to its provide our the make
pivotal NS and on engaging Pharma while enrolling path exploring are relationship We the our regulatory forward our CAP-XXXX trial with strengthening OUS FDA and for partnerships. our
San Our nearing technology potential Diego now organization, the into year have and that a significantly maturing can is our hiring a a future entering One strategy revenue is platform for completion. facility, has assembled of partnerships moving business our new across after great team progressed we and a platform with exosome plan into new stream. create phase
that will I on balance financial the organization across over continue our entering support financials. for the momentum. AJ update Bergmann, observe Financial believe structure and now call strong with will a discipline AJ? organizational the turn XXXX Officer, Chief current to We will our detailed and to more sheet
